CardioMEMS HF System; Merlin.net PCN HF Portal (Model MN6000); CardioMEMS Backend Web Application (Model CM4000); HF Clo
ABBOTT MEDICAL · Decision date Sep 30, 2026
What did the FDA approve?
On 2026-09-30, FDA recorded an approval decision on P100045/S091, a PMA supplement submitted by Abbott Medical under the real-time process pathway, with the stated reason being a change in design, components, specifications or material. The supplement covers proposed modifications to the Merlin.net Patient Care Network Heart Failure Portal (Model MN6000) and the CardioMEMS Backend Web Application (Model CM4000) that together make up the HF Cloud Software Version C2.1 update.
The underlying device is categorized as an implantable hemodynamic system within the cardiovascular specialty, product code MOM. This action concerns the software components named in the supplement statement rather than a new approval of the full CardioMEMS HF System. The source record does not describe the specific software changes, their technical rationale, or any supporting documentation, so those details remain unknown.
The record also does not include clinical performance data, labeling changes, or any determination about effects on patient management, and none should be inferred from the approval alone.
FDA approval order statement
proposed modifications to the Merlin.net Patient Care Network (PCN) Heart Failure (HF) Portal (Model MN6000) and the CardioMEMS Backend Web Application (Model CM4000), that comprise the HF Cloud Software Version C2.1 update.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 30, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P100045/S091
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- MOM
- Decision code
- APPR
- Decision date
- Sep 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, hemodynamic, implantable.
- Applicant
- Abbott Medical
- Product code
- MOM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P100045. Subsequent supplements may change the device or its indications.
FDA decision timeline
P100045 · Original PMA
CARDIOMEMS HF PRESSURE MEASUREMENT SYSTEM
P100045/S091 received
Application receipt date recorded by FDA.
P100045/S092 · Related supplement
CardioMEMS PA Sensor and Delivery System (CM2000); CardioMEMS HF System
P100045/S093 · Related supplement
CardioMEMS PA Sensor and Delivery System
P100045/S091 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P100045. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100045
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA approval | May 28, 2014 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Sep 11, 2026 | FDA | |
CardioMEMS PA Sensor and Delivery SystemP100045/S093 | ABBOTT MEDICAL | PMA supplement | Sep 30, 2026 | FDA |
Explore the linked device profile
Other records with product code MOM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Cordella Pulmonary Artery Sensor SystemP230040/S030 | Endotronix, Inc. | PMA supplement | Oct 29, 2026 | FDA |
| Endotronix, Inc. | PMA supplement | Oct 20, 2026 | FDA | |
| Endotronix, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Endotronix, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
| Endotronix, Inc. | PMA supplement | Sep 25, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 387 Nerem St. NW, Suite #500, Atlanta, GA, 30313
Sources and methodology
- Original FDA record: P100045/S091
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




